Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 452

1.

Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study.

Cannizzo E, Raia M, De Propris MS, Triolo A, Scarpati B, Marfia A, Stacchini A, Buccisano F, Lanza F, Regazzoli A, Michelutti A, Cesaro S, Conte CA, Vanelli L, Tedone E, Omedè P, Ciriello MM, Caporale R, Catinella V, Pantano G, De Rosa C, Lo Pardo C, Poletti G, Ulbar F, Pavanelli MC, Del Pup L, Ottaviano V, Santonocito AM, Bartocci C, Boscaro E, Arras M, Amodeo R, Mestice A, Oliva B, Ferrari L, Statuto T, D'Auria F, Pianezze G, Tanca D, Visconte F, Rubba F, Musto P, Geuna M, Gatti A, Brando B, Del Vecchio L.

Ann Hematol. 2019 Mar 13. doi: 10.1007/s00277-019-03644-8. [Epub ahead of print]

PMID:
30868306
2.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Feb 28. pii: haematol.2018.205054. doi: 10.3324/haematol.2018.205054. [Epub ahead of print]

3.

Thalidomide-induced psoriasis in a patient with multiple myeloma.

D'Arena G, Galdo G, Musto P.

Postgrad Med J. 2019 Feb 26. pii: postgradmedj-2018-136317. doi: 10.1136/postgradmedj-2018-136317. [Epub ahead of print] No abstract available.

PMID:
30808723
4.

An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers.

De Luca L, Laurenzana I, Trino S, Lamorte D, Caivano A, Musto P.

Expert Rev Mol Diagn. 2019 Mar;19(3):249-258. doi: 10.1080/14737159.2019.1583103. Epub 2019 Feb 26.

PMID:
30782029
5.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase 1/2 studies.

Bringhen S, Mina R, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Caravita di Toritto T, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A.

Haematologica. 2019 Feb 7. pii: haematol.2018.208272. doi: 10.3324/haematol.2018.208272. [Epub ahead of print]

6.

Sorption Thermodynamics of CO₂, H₂O, and CH₃OH in a Glassy Polyetherimide: A Molecular Perspective.

Mensitieri G, Scherillo G, La Manna P, Musto P.

Membranes (Basel). 2019 Feb 1;9(2). pii: E23. doi: 10.3390/membranes9020023.

7.

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.

Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, Musto P, Petrucci MT, Barosi G.

Blood Rev. 2019 Mar;34:84-94. doi: 10.1016/j.blre.2019.01.001. Epub 2019 Jan 9. Review.

PMID:
30683446
8.

Monoclonal B-cell lymphocytosis and prostate cancer: incidence and effects of radiotherapy.

D'Auria F, Valvano L, Rago L, Statuto T, Calice G, D'Arena G, Fusco V, Musto P.

J Investig Med. 2019 Jan 11. pii: jim-2018-000902. doi: 10.1136/jim-2018-000902. [Epub ahead of print]

PMID:
30635362
9.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

10.

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P.

Blood Rev. 2019 Mar;34:16-25. doi: 10.1016/j.blre.2018.10.002. Epub 2018 Oct 28. Review.

PMID:
30448050
11.

Evolution of monoclonal antibodies in multiple myeloma.

Musto P.

Lancet Oncol. 2018 Dec;19(12):1554-1555. doi: 10.1016/S1470-2045(18)30647-8. Epub 2018 Nov 12. No abstract available.

PMID:
30442500
12.

Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells.

Lamorte D, Faraone I, Laurenzana I, Milella L, Trino S, De Luca L, Del Vecchio L, Armentano MF, Sinisgalli C, Chiummiento L, Russo D, Bisaccia F, Musto P, Caivano A.

Int J Mol Sci. 2018 Oct 26;19(11). pii: E3348. doi: 10.3390/ijms19113348.

13.

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).

Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A.

Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23.

PMID:
30353388
14.

Functionalized Gold Nanoparticles as Biosensors for Monitoring Cellular Uptake and Localization in Normal and Tumor Prostatic Cells.

Pannico M, Calarco A, Peluso G, Musto P.

Biosensors (Basel). 2018 Oct 4;8(4). pii: E87. doi: 10.3390/bios8040087.

15.

Global methylation patterns in primary plasma cell leukemia.

Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M, Fabris S, Barbieri M, Pompa A, Baldini L, Bollati V, Zoppoli P, Neri A, Musto P.

Leuk Res. 2018 Oct;73:95-102. doi: 10.1016/j.leukres.2018.09.007. Epub 2018 Sep 18.

PMID:
30257227
16.

Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.

D'Arena G, Seneca E, Migliaccio I, De Feo V, Giudice A, La Rocca F, Capunzo M, Calapai G, Festa A, Caraglia M, Musto P, Iorio EL, Ruggieri V.

Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317. [Epub ahead of print]

PMID:
30234409
17.

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.

Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A.

Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Review.

PMID:
30196909
18.

Meningeal Involvement in Primary Plasma Cell Leukemia.

D'Arena G, Bitetti C, Daraia B, Pietrantuono G, Musto P.

Indian J Hematol Blood Transfus. 2018 Jul;34(3):556-557. doi: 10.1007/s12288-018-0943-z. Epub 2018 Mar 12. No abstract available.

PMID:
30127574
19.

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V.

Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. No abstract available.

20.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

PMID:
30038381
21.

Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies.

Laurenzana I, Lamorte D, Trino S, De Luca L, Ambrosino C, Zoppoli P, Ruggieri V, Del Vecchio L, Musto P, Caivano A, Falco G.

Stem Cells Int. 2018 May 27;2018:9863194. doi: 10.1155/2018/9863194. eCollection 2018. Review.

22.

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Spagnoli A, Voso MT, Fianchi L, Papayannidis C, Gaidano GL, Breccia M, Musto P, De Bellis E, Del Principe MI, Lunghi M, Lessi F, Martinelli G, Venditti A.

Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.

PMID:
29947973
23.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
24.

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?

Musto P.

Oncologist. 2018 May;23(5):511-515. doi: 10.1634/theoncologist.2018-0097. Epub 2018 Apr 26. No abstract available.

25.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
26.

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L.

Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2510. [Epub ahead of print]

PMID:
29602219
27.

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.

Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8.

PMID:
29520559
28.

Pseudomembranous colitis in acute lymphoblastic leukaemia.

D'Arena G, Pietrantuono G, Musto P.

Postgrad Med J. 2018 Jun;94(1112):361. doi: 10.1136/postgradmedj-2018-135605. Epub 2018 Mar 2. No abstract available.

PMID:
29500180
29.

Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.

D'Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M, Calapai G, Laurenti L, Musto P, Di Minno G, Fenoglio D.

J Immunol Res. 2017;2017:1832968. doi: 10.1155/2017/1832968. Epub 2017 Dec 21. Review.

30.

MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.

Trino S, Lamorte D, Caivano A, Laurenzana I, Tagliaferri D, Falco G, Del Vecchio L, Musto P, De Luca L.

Int J Mol Sci. 2018 Feb 3;19(2). pii: E460. doi: 10.3390/ijms19020460. Review.

31.

Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.

Cosimato V, Scalia G, Raia M, Gentile L, Cerbone V, Visconte F, Statuto T, Valvano L, D'Auria F, Calice G, Graziano D, Musto P, Del Vecchio L.

Leuk Lymphoma. 2018 Sep;59(9):2242-2245. doi: 10.1080/10428194.2017.1416366. Epub 2018 Jan 15. No abstract available.

PMID:
29334284
32.

Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.

Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, Di Nardo E, Perseghin P, Olivieri A.

Bone Marrow Transplant. 2018 Apr;53(4):461-473. doi: 10.1038/s41409-017-0051-y. Epub 2018 Jan 12.

PMID:
29330395
33.

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.

PMID:
29263440
34.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

35.

Unusual Hypergranular Myelomatous Plasma Cells.

D'Arena G, Musto P.

Indian J Hematol Blood Transfus. 2017 Dec;33(4):617-618. doi: 10.1007/s12288-017-0786-z. Epub 2017 Jan 30. No abstract available.

36.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators.

Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24.

PMID:
28838276
37.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.

38.

Octupolar Metastructures for a Highly Sensitive, Rapid, and Reproducible Phage-Based Detection of Bacterial Pathogens by Surface-Enhanced Raman Scattering.

Rippa M, Castagna R, Pannico M, Musto P, Borriello G, Paradiso R, Galiero G, Bolletti Censi S, Zhou J, Zyss J, Petti L.

ACS Sens. 2017 Jul 28;2(7):947-954. doi: 10.1021/acssensors.7b00195. Epub 2017 Jun 20.

PMID:
28750539
39.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M.

J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.

40.

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A.

Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

PMID:
28721629
41.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

42.

Do we need to distinguish exosomes from microvesicles in hematological malignancies?

Caivano A, Del Vecchio L, Musto P.

Leukemia. 2017 Sep;31(9):2009-2010. doi: 10.1038/leu.2017.205. Epub 2017 Jun 28. No abstract available.

PMID:
28656959
43.

Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Perbellini O, Coscia M, La Rocca F, Ruggieri V, Visco C, Di Minno NMD, Innocenti I, Pizza V, Deaglio S, Di Minno G, Giudice A, Calapai G, Musto P, Laurenti L, Iorio EL.

Eur J Haematol. 2017 Oct;99(4):306-314. doi: 10.1111/ejh.12918. Epub 2017 Aug 3.

PMID:
28646624
44.

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.

Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation).

Am J Hematol. 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. No abstract available.

45.

Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy.

Caivano A, La Rocca F, Laurenzana I, Trino S, De Luca L, Lamorte D, Del Vecchio L, Musto P.

Int J Mol Sci. 2017 Jun 2;18(6). pii: E1183. doi: 10.3390/ijms18061183. Review.

46.

Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.

De Luca L, Trino S, Laurenzana I, Tagliaferri D, Falco G, Grieco V, Bianchino G, Nozza F, Campia V, D'Alessio F, La Rocca F, Caivano A, Villani O, Cilloni D, Musto P, Del Vecchio L.

Cell Death Dis. 2017 Jun 1;8(6):e2849. doi: 10.1038/cddis.2017.253.

47.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2018 Apr 1;29(4):1074. doi: 10.1093/annonc/mdx160. No abstract available.

PMID:
28541409
48.

Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?

De Luca L, Trino S, Laurenzana I, Lamorte D, Caivano A, Del Vecchio L, Musto P.

Int J Mol Sci. 2017 May 9;18(5). pii: E1022. doi: 10.3390/ijms18051022. Review.

49.

Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response.

D'Auria F, La Rocca F, Simeon V, Statuto T, Pietrantuono G, D'Arena G, Villani O, Mansueto G, Traficante A, Musto P.

Br J Haematol. 2018 May;181(4):550-552. doi: 10.1111/bjh.14662. Epub 2017 Apr 25. No abstract available.

PMID:
28439880
50.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L.

Int J Mol Sci. 2017 Apr 14;18(4). pii: E837. doi: 10.3390/ijms18040837.

Supplemental Content

Support Center